Welcome to the ACR/ARHP Abstracts Website
There are several ways to explore this site:
- Browse 2015 abstracts in numerical order.
- Browse 2015 abstracts by viewing the list of session titles.
- View abstracts about a certain topic by visiting the keyword index.
- Search this site for a specific abstract.
- Access the meetings archive to view abstracts from previous meetings.
- Register or log in to save favorites.
2015 Late-Breaking Abstracts
- Abstract Number: 1L
Tocilizumab for the Treatment of Giant Cell Arteritis – a Randomized Placebo-Controlled Trial
- Abstract Number: 2L
Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
- Abstract Number: 3L
A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis
- Abstract Number: 4L
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
- Abstract Number: 5L
Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomized, Placebo-Controlled, Dose-Ranging Study
- Abstract Number: 6L
Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab
- Abstract Number: 7L
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015
- Abstract Number: 8L
A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)
- Abstract Number: 9L
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis
- Abstract Number: 10L
Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen
- Abstract Number: 11L
Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients with Primary Sjogrens Syndrome
- Abstract Number: 12L
Assessment of Immunogenicity of Live Zoster Vaccination (Zostavax®) in Rheumatoid Arthritis Patients on Background Methotrexate before and after Initiating Tofacitinib or Placebo
- Abstract Number: 13L
Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
- Abstract Number: 14L
Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
- Abstract Number: 15L
Identification of Four-and-a-Half-LIM Domain 1 (FHL1) As a New Autoantibody Target in Idiopathic Inflammatory Myopathies